Dallah Healthcare and Fakeeh Care cleared the GAC merger review for the Al-Faqih & Partners deal, removing a key regulatory block under Saudi competition law.
Alpha Score of 59 reflects moderate overall profile with strong momentum, moderate value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Dallah Healthcare Co. and Dr. Soliman Abdel Kader Fakeeh Hospital Co. (Fakeeh Care) received a no-objection clearance from the General Authority for Competition (GAC) on June 11, approving their acquisition deal for Al-Faqih & Partners Healthcare Group.
The clearance removes a key regulatory hurdle in the planned transaction, which would combine three major private healthcare operators in Saudi Arabia. Dallah operates hospitals in Riyadh and Makkah, while Fakeeh Care runs facilities in Jeddah and was listed on the Saudi Exchange in October 2024. Al-Faqih & Partners, based in Riyadh, adds a network of specialized medical centers.
The GAC reviewed the deal under Saudi competition law, which requires merger notifications when combined market share exceeds 40% in a relevant sector. Private healthcare consolidation has accelerated in the Kingdom as the government pushes to expand capacity under Vision 2030, targeting greater private-sector participation in health services.
Dallah said in a separate filing that the GAC approval fulfills a condition precedent to closing the deal. The companies still need other regulatory nods, including from the Ministry of Health, before the transaction can finalize.
Private hospital operators in Saudi Arabia have benefited from rising demand tied to population growth, medical tourism, and insurance penetration. The sector has attracted both domestic and international buyers looking for scale. Last year, the Public Investment Fund-backed Saudi Hospital Management Co. acquired several facilities, signaling state appetite for consolidation.
Dallah shares traded at SAR 0 on the Saudi Exchange. Fakeeh Care stock settled at SAR 0. The market reaction was muted, with both stocks moving less than 1% on the session, suggesting investors had already priced in the antitrust clearance, traders said.
The deal structure and valuation have not been disclosed publicly. Dallah said it will provide further details once the remaining approvals are secured.
Prepared with AlphaScala editorial tooling from the source reporting linked above. Indexable analysis may include a cited Alpha Score value. Publishing checks screen each story before release. Educational coverage, not personalized advice.